IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs - PubMed (original) (raw)
IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs
S Fiorucci et al. J Immunol. 2000.
Abstract
Caspase-1, the IL-1beta converting enzyme (ICE), is required for intracellular processing/maturation of IL-1beta and IL-18. NO releasing nonsteroidal antiinflammatory drugs (NSAIDs) are a new class of NSAID derivatives that spare the gastric mucosa. Here, we tested the hypothesis that NCX-4016, a NO-aspirin derivative, inhibits proinflammatory cytokine release from endotoxin (LPS)-challenged monocytes. Our results demonstrated that exposing LPS-stimulated human monocytes to NCX-4016 resulted in a 40-80% inhibition of IL-1beta, IL-8, IL-12, IL-18, IFN-gamma, and TNF-alpha release with an EC(50) of 10-20 microM for IL-1beta and IL-18. Incubating LPS-primed monocytes with NCX-4016 resulted in intracellular NO formation as assessed by measuring nitrite/nitrate, intracellular cGMP concentration, and intracellular NO formation. Exposing LPS-stimulated monocytes to aspirin or celecoxib caused a 90% inhibition of prostaglandin E(2) generation but had no effect on cytokine release. NCX-4016, similar to the NO donor S-nitroso-N-acetyl-D-L-penicillamine, inhibited caspase-1 activity with an EC(50) of approximately 20 microM. The inhibition of caspase-1 by NCX-4016 was reversible by the addition of DTT, which is consistent with S-nitrosylation as the mechanism of caspase-1 inhibition. NCX-4016, but not aspirin, prevented ICE activation as measured by assessing the release of ICE p20 subunit. IL-18 immunoneutralization resulted in a 60-80% reduction of IL-1beta, IL-8, IFN-gamma, and TNF-alpha release from LPS-stimulated monocytes. Taken together, these data indicate that incubating human monocytes with NCX-4016 causes intracellular NO formation and suppresses IL-1beta and IL-18 processing by inhibiting caspase-1 activity. Caspase-1 inhibition is a new, cycloxygenase-independent antiinflammatory mechanism of NO-aspirin.
Similar articles
- Nitric oxide-releasing NSAIDs inhibit interleukin-1beta converting enzyme-like cysteine proteases and protect endothelial cells from apoptosis induced by TNFalpha.
Fiorucci S, Santucci L, Federici B, Antonelli E, Distrutti E, Morelli O, Renzo GD, Coata G, Cirino G, Soldato PD, Morelli A. Fiorucci S, et al. Aliment Pharmacol Ther. 1999 Mar;13(3):421-35. doi: 10.1046/j.1365-2036.1999.00442.x. Aliment Pharmacol Ther. 1999. PMID: 10102977 - Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats.
Fiorucci S, Antonelli E, Santucci L, Morelli O, Miglietti M, Federici B, Mannucci R, Del Soldato P, Morelli A. Fiorucci S, et al. Gastroenterology. 1999 May;116(5):1089-106. doi: 10.1016/s0016-5085(99)70012-0. Gastroenterology. 1999. PMID: 10220501 - NO-releasing NSAIDs are caspase inhibitors.
Fiorucci S. Fiorucci S. Trends Immunol. 2001 May;22(5):232-5. doi: 10.1016/s1471-4906(01)01904-4. Trends Immunol. 2001. PMID: 11323270 Review. - Interleukin-1beta converting enzyme (caspase-1) in intestinal inflammation.
Siegmund B. Siegmund B. Biochem Pharmacol. 2002 Jul 1;64(1):1-8. doi: 10.1016/s0006-2952(02)01064-x. Biochem Pharmacol. 2002. PMID: 12106600 Review.
Cited by
- Inflammasome activation of IL-1 family mediators in response to cutaneous photodamage.
Nasti TH, Timares L. Nasti TH, et al. Photochem Photobiol. 2012 Sep-Oct;88(5):1111-25. doi: 10.1111/j.1751-1097.2012.01182.x. Epub 2012 Jul 9. Photochem Photobiol. 2012. PMID: 22631445 Free PMC article. Review. - Protein nitration and nitrosylation by NO-donating aspirin in colon cancer cells: Relevance to its mechanism of action.
Williams JL, Ji P, Ouyang N, Kopelovich L, Rigas B. Williams JL, et al. Exp Cell Res. 2011 Jun 10;317(10):1359-67. doi: 10.1016/j.yexcr.2011.03.001. Epub 2011 Mar 22. Exp Cell Res. 2011. PMID: 21406194 Free PMC article. - A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages.
Turnbull CM, Marcarino P, Sheldrake TA, Lazzarato L, Cena C, Fruttero R, Gasco A, Fox S, Megson IL, Rossi AG. Turnbull CM, et al. J Inflamm (Lond). 2008 Jul 31;5:12. doi: 10.1186/1476-9255-5-12. J Inflamm (Lond). 2008. PMID: 18671842 Free PMC article. - Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.
Wesolowski R, Markowitz J, Carson WE 3rd. Wesolowski R, et al. J Immunother Cancer. 2013 Jul 15;1:10. doi: 10.1186/2051-1426-1-10. eCollection 2013. J Immunother Cancer. 2013. PMID: 24829747 Free PMC article. Review. - COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation.
Hoogstraate J, Andersson LI, Berge OG, Jonzon B, Ojteg G. Hoogstraate J, et al. Inflammopharmacology. 2003;11(4):423-8. doi: 10.1163/156856003322699591. Inflammopharmacology. 2003. PMID: 15035795
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous